ERBITUX(Cetuximab) approved for treatment of KRAS wild type metastatic colorectal cancer

Published: 2008-10-14 06:42:00

Updated: 2008-10-14 06:42:00

Merck Korea announced on October 8 that the Korea Food and Drug Administration has approved Erbitux (cetuximab), a first-in-class and highly active IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), for treatment of patients with KRAS wild type metastatic colorectal c...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK